FDA Reverses Course on Regenxbio Gene Therapy, Third Rare Disease Drug Reversal

What's happening

REGENXBIO Inc. (Nasdaq: RGNX) announced on June 22, 2026 that it has reached alignment with the FDA on a regulatory path forward for the BLA resubmission of NAVSUNLI (RGX-121), its investigational gene therapy for mucopolysaccharidosis type II, commonly known as Hunter syndrome. The announcement came approximately four months after the FDA issued a Complete Response Letter in February 2026, which had previously rejected the application. Critically, the FDA confirmed that no additional clinical studies or new patients would be required to support resubmission; instead, longer-term data from the existing CAMPSIITE study will be reviewed on an expedited basis. REGENXBIO intends to request a Type A meeting with the FDA to review biomarker and clinical data prior to resubmission, and the company expects to file the BLA resubmission in Q3 2026, targeting accelerated approval as what would be the first gene therapy approved for MPS II.

The development represents the third instance in a matter of days in which the FDA has reversed course on a rare disease drug, a pattern that has drawn attention across the biotech regulatory landscape. REGENXBIO stated: 'We will continue to work closely with the FDA and remain focused on bringing this important therapy to boys living with Hunter syndrome as quickly as possible.' The company had previously announced a strategic partnership with NS Pharma, Inc. in January 2025 for commercialization of NAVSUNLI following potential FDA approval, a commercial infrastructure arrangement that would be activated if the resubmission ultimately succeeds.

Why it matters for markets

The FDA's willingness to accept a resubmission without requiring additional studies materially reduces both the time and capital burden that REGENXBIO would otherwise face. With a market capitalization of $468.9 million and annual revenue of $87.8 million, the company operates at a scale where the commercial outcome of a single rare-disease approval can be transformative to its financial profile. The accelerated approval pathway, if granted, would allow NAVSUNLI to reach the market based on a surrogate or intermediate clinical endpoint reasonably likely to predict clinical benefit, with confirmatory trials to follow — a mechanism specifically designed to expedite access for serious conditions with unmet medical need such as Hunter syndrome.

The premarket trading reaction on June 22, 2026 reflected the significance of the announcement, with reported moves ranging from 10% to 37% across different data points, against a 52-week range of $5.46 to $16.19 for RGNX shares. The broader implication extends beyond REGENXBIO: the FDA's pattern of reversals on rare disease drugs within a compressed timeframe signals a potential shift in the agency's posture toward accelerated approval mechanisms for gene therapies, a category that has faced heightened regulatory scrutiny in recent years. For developers using AAV-vector platforms — the technology underlying REGENXBIO's proprietary NAV Technology Platform — a more receptive regulatory environment could reduce the risk premium historically associated with late-stage gene therapy programs.

The pre-existing commercialization partnership with NS Pharma, Inc., established in January 2025, means that REGENXBIO has already structured a go-to-market arrangement contingent on approval. The activation of that partnership upon a successful BLA outcome would represent a defined commercial pathway for a therapy targeting a rare pediatric population with limited existing treatment options.

Sectors and assets to watch

The primary ticker directly affected is REGENXBIO (Nasdaq: RGNX), whose pipeline is anchored by RGX-121 for MPS II and RGX-314 for wet age-related macular degeneration and diabetic retinopathy, both built on its NAV Technology Platform using adeno-associated virus vectors. The company's 371-person workforce and $87.8 million revenue base are sized around a licensing and development model, making a potential first-in-class approval for Hunter syndrome a significant potential inflection point for its commercial trajectory. The NS Pharma partnership for commercialization, announced in January 2025, is the most directly activated adjacent relationship to monitor.

More broadly, the gene therapy sector warrants attention given the FDA's third rare disease drug reversal within days. Companies developing AAV-based gene therapies for rare pediatric and metabolic disorders operate in a regulatory environment where the accelerated approval pathway has historically been both a lifeline and a source of uncertainty. The pattern of recent FDA reversals may be relevant context for other developers navigating similar Complete Response Letter situations, though the specific regulatory and clinical circumstances of each program differ.

What to watch next

The immediate milestone to monitor is REGENXBIO's formal request for a Type A meeting with the FDA, which would set the agenda for reviewing biomarker and clinical data from the CAMPSIITE study ahead of BLA resubmission. The company has guided for resubmission in Q3 2026, making the July–September window the critical near-term timeline. Investors and analysts will be watching whether the FDA's expedited review of the longer-term CAMPSIITE data proceeds without further requests for information, and whether the accelerated approval designation is formally confirmed as part of the resubmission framework. The activation timeline for the NS Pharma commercialization partnership, and any further FDA communications regarding the broader pattern of rare disease drug reversals, will also be closely followed across the gene therapy sector.